The immune system in cancer

Integrative Cancer Therapies

Volumn 1, Issue 3, 2002, Pages 294-316

  Block, Keith I ^a   Boyd, D Barry ^b   Gonzalez, Nicholas ^d   Vojdani, Aristo ^c  

^a Block Center Integrative Cancer Care   (United States)

^b Integrative Oncology   (United States)

^c Immunosciences Laboratories Inc   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BETA ENDORPHIN; CANCER VACCINE; CELL SURFACE RECEPTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ICOSAPENTAENOIC ACID; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; BREAST CARCINOMA; CANCER; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; HEAD AND NECK CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STRESS; T LYMPHOCYTE; VIRUS INFECTION; ZINC DEFICIENCY; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; RADIATION EXPOSURE;

HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 0041321178     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/153473540200100314     Document Type: Review

References (35)

1. Burnet FM. Immunological factors in the process of carcinogenesis. Br Med Bull. 1964;20:154-158.
2. Burner FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1-8.
3. Botti C, Seregni E, Ferrari L, Martinetti A, Bombardieri E. Immunosuppressive factors: role in cancer development and progression. Int J Biol Markers. 1998;13(2):51-69.
4. Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing. Mol Med. 2000;6:465-479.
5. Berghella AM, Pellegrini P, Del Beato T, Marini M, Tomei E, Adorno D, et al. The significance of an increase in soluble interleukin-2 receptor level in colorectal cancer and its biological regulating role in the physiological switching of the immune response cytokine network from TH1 to TH2 and back. Cancer Immunol Immunother. 1998;45:241-249.
6. Sheu BC, Hsu SM, Ho HN, Lin RH, Huang SC. Tumor immunology-when a cancer cell meets the immune cells.J Formosan Med Assoc. 1999;98:730-735.
7. Oliver RT, Nouri AM. T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surveys. 1992;13:173-204.
8. Erickson KL. Mechanisms of dietary fat modulation of tumorigenesis: changes in immune response. Prog Clin Biol Res. 1986;222:555-586.
9. Calder PC. Fatty acids, dietary, lipids and lymphocyte functions. Biochem Soc Trans. 1995;23:302-309.
10. Yaqoob P, Newsholme EA, Calder PC. Inhibition of natural killer cell activity by dietary lipids. Immunol Lett. 1994;41(23):241-247.
11. Boissonneault GA, Elson CE, Pariza MW. Dietary fat and neoplasia-the role of net energy in enhancement of carcinogenesis: effects of fat and calories on the immune system. Adv Exp Med Biol. 1986;206:85-98.
12. Hoffman-Goetz L, Apter D, Demark-Wahnefried W, Goran MI, McTiernan A, Reichman ME. Possible mechanisms mediating an association between physical activity and breast cancer. Cancer 1998;83(3 suppl):621-628.
13. Jadeski L, Hoffman-Goetz L. Exercise and in vivo natural cytotoxicity against tumour cells of varying metastatic capacity. Clin Exp Metastasis. 1996;14:138-144.
14. Woods JA, Davis JM, Smith JA, Nieman DC. Exercise and cellular innate immune function. Med Sci Sports Exerc. 1999;31(1):57-66.
15. Peters ML, Godaert GL, Ballieux RE, Brosschot JF, Sweep FC, Swinkels LM, et al. Immune responses to experimental stress: effects of mental effort and uncontrollability. Psychosom Med. 1999;61:513-524.
16. Pike JL, Smith TL, Hauger RL, Nicassio PM, Patterson TL, McClintick J, et al. Chronic life stress alters sympathetic, neuroendocrine, and immune responsivity to an acute psychological stressor in humans. Psychosom Med. 1997;59:447-457.
17. Delahanty DL, Dougall AL, Craig KJ, Jenkins FJ, Baum A. Chronic stress and natural killer cell activity after exposure to traumatic death. Psychosom Med. 1997;59:467-476.
18. Arteaga CL, Carty-Dugger T, Moses HL, Hurd S, Pietenpol J. Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth Differentiation. 1993;4:193-201.
19. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type-beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A. 1986;83:4167-4171.
20. Keski-Oja J, Blasi F, Leof EB, Moses HL. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-beta. J Cell Biol. 1988;106:451-459.
21. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res. 1989;49:2533-2553.
22. Kehrl JH, Wakefield LM, Roberts AB, Jakolew S, Alvarez-Mon M, Derynck R, et al. Production of transforming growth factor beta by T lymphocytes and its potential in the regulation of T cell growth. J Exp Med. 1986;163:1037-1050.
23. Kehrl JH, Roberts AB, Wakefield LM, Jakolew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol. 1986;137:3855-3860.
24. Tsunawaki S, Sporn M, Ding A, Nathan C. Deactivation of macrophages by transforming growth factor-beta. Nature (London). 1988;334:260-262.
25. De Visser KE, Kast WM. Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia. 1999;13:1188-1199.
26. Wilson SD, McCay JA, Butterworth LF, Munson AE, White KL Jr. Correlation of suppressed natural killer cell activity with altered host resistance models in B6C3F1 mice. Toxicol Appl Pharmacol. 2001;177:208-218.
27. Heuser G, Vojdani A. Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C. Immunopharmacol Immunotoxicol. 1997;19:291-312.
28. Podmore ID, Griffiths HR, Herbert KE, Mistry N, Mistry P, Lunec J. Vitamin C exhibits pro-oxidant properties. Nature. 1998;392:559.
29. Vojdani A, Bazargan M, Vojdani E, Wright J. New evidence for antioxidant properties of vitamin C. Cancer Detect Prev. 2000;24:508-523.
30. Williams GM, Williams CL, Weisburger JH. Diet and cancer prevention: the fiber first diet. Toxicol Sci. 1999;52 (2 suppl):72-86.
31. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35(1):23-28.
32. Yamasaki S, Kan N, Harada T, Ichinose Y, Moriguchi Y, Li L, et al. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res Treat. 1993;26(1):55-65.
33. Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y, Sugimachi K. Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis. Am J Gastroenterol. 2001;96:574-578.
34. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79:2320-2328.
35. Wong PY, Staren ED, Tereshkova N, Braun DP. Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res. 1998;76:95-103.